Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities: 2021-2025

  • ARS Pharmaceuticals' Other Non-Current Liabilities was N/A to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year change of. This contributed to the annual value of $83,000 for FY2021, which is N/A change from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Other Non-Current Liabilities stood at $3.8 million, which was up 166.64% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $3.8 million in Q3 2025 and a low of $83,000 during Q4 2021.
  • Moreover, its 1-year median value for Other Non-Current Liabilities was $2.6 million (2025), whereas its average is $2.6 million.